Literature DB >> 27199314

The role of peripheral afferents in persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled, crossover trial of ultrasound-guided tender point blockade.

N Wijayasinghe1, T K Ringsted2, J M Bischoff2, H Kehlet3, M U Werner2.   

Abstract

BACKGROUND: Severe, persistent inguinal postherniorrhaphy pain (PIPP) is a debilitating condition that develops in 2-5% of patients. PIPP may be neuropathic in nature, yet the lesion in the peripheral nervous system has not been located. Most PIPP-patients demonstrate a tender point (TP) in the medial aspect of the inguinal region that triggers pain upon minimal pressure. As TPs may play a role in the pathophysiology of PIPP, the aim of this trial was to investigate the analgesic effects of local anaesthetic TP-blockade.
METHODS: A randomized, double-blind, placebo-controlled, crossover trial was performed in 14 PIPP-patients and six healthy volunteers. All participated in two sessions, seven days apart, receiving 10 ml of 0.25% bupivacaine or normal saline via an ultrasound-guided fascial plane block at the TP. The TP-area was used for pain assessments (at rest, on movement, with 100 kPa pressure-algometry) and quantitative sensory testing (pressure pain thresholds, thermal detection/pain thresholds, supra-threshold heat perception), before and after the TP-blockade.
RESULTS: The median (95% CI) reduction in pain was 63% (44.1 to 73.6%) after bupivacaine compared with 36% (11.6 to 49.7%; P=0.003) after placebo. Significant increases in cool detection (P=0.01) and pressure pain thresholds (P=0.009) with decreases in supra-threshold heat pain perception (P=0.003) were seen after bupivacaine only. In four out of six volunteers, increased thermal and evoked-pain thresholds after bupivacaine compared with placebo, was demonstrated.
CONCLUSIONS: This trial demonstrates that peripheral afferent input from the TP-area is important for maintenance of spontaneous and evoked pain in PIPP. CLINICAL TRIAL REGISTRATION: NCT02065219.
© The Author 2016. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  bupivacaine; chronic pain; herniorrhaphy; inguinal hernia; nerve blockade; randomized controlled trial

Mesh:

Substances:

Year:  2016        PMID: 27199314      PMCID: PMC4872862          DOI: 10.1093/bja/aew071

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  24 in total

Review 1.  The revised CONSORT statement for reporting randomized trials: explanation and elaboration.

Authors:  D G Altman; K F Schulz; D Moher; M Egger; F Davidoff; D Elbourne; P C Gøtzsche; T Lang
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

2.  Myofascial pain in patients with postthoracotomy pain syndrome.

Authors:  H Hamada; K Moriwaki; K Shiroyama; H Tanaka; M Kawamoto; O Yuge
Journal:  Reg Anesth Pain Med       Date:  2000 May-Jun       Impact factor: 6.288

3.  The visual analogue pain intensity scale: what is moderate pain in millimetres?

Authors:  S L Collins; R A Moore; H J McQuay
Journal:  Pain       Date:  1997-08       Impact factor: 6.961

4.  Groin pain in the absence of hernia: a new syndrome.

Authors:  M Deysine; G R Deysine; W P Reed
Journal:  Hernia       Date:  2002-07       Impact factor: 4.739

5.  Analysis of serial measurements in medical research.

Authors:  J N Matthews; D G Altman; M J Campbell; P Royston
Journal:  BMJ       Date:  1990-01-27

6.  Chronic pain after groin hernia repair.

Authors:  H Kehlet
Journal:  Br J Surg       Date:  2008-02       Impact factor: 6.939

7.  Prolonged relief of neuralgia after regional anesthetic blocks. A call for further experimental and systematic clinical studies.

Authors:  Staffan Arnér; Ulf Lindblom; Björn A Meyerson; Carl Molander
Journal:  Pain       Date:  1990-12       Impact factor: 6.961

8.  Treatment for persistent chronic neuralgia after inguinal hernioplasty.

Authors:  P Palumbo; A Minicucci; A G Nasti; I Simonelli; F Vietri; A M Angelici
Journal:  Hernia       Date:  2007-08-01       Impact factor: 4.739

9.  Painful neuropathy: altered central processing maintained dynamically by peripheral input.

Authors:  Richard H Gracely; Sue A Lynch; Gary J Bennett
Journal:  Pain       Date:  1992-11       Impact factor: 6.961

10.  A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial.

Authors:  Joakim M Bischoff; Thomas K Ringsted; Marian Petersen; Claudia Sommer; Nurcan Uçeyler; Mads U Werner
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

View more
  6 in total

Review 1.  Neuropathic Pain: Central vs. Peripheral Mechanisms.

Authors:  Kathleen Meacham; Andrew Shepherd; Durga P Mohapatra; Simon Haroutounian
Journal:  Curr Pain Headache Rep       Date:  2017-06

Review 2.  Management of chronic pain after hernia repair.

Authors:  Kristoffer Andresen; Jacob Rosenberg
Journal:  J Pain Res       Date:  2018-04-05       Impact factor: 3.133

Review 3.  Chronic postoperative pain: recent findings in understanding and management.

Authors:  Darin Correll
Journal:  F1000Res       Date:  2017-07-04

4.  A national center for persistent severe pain after groin hernia repair: Five-year prospective data.

Authors:  Elisabeth Kjær Jensen; Thomas K Ringsted; Joakim M Bischoff; Morten A Petersen; Jacob Rosenberg; Henrik Kehlet; Mads U Werner
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

5.  Pulsed radiofrequency for chronic post-herniorrhaphy inguinal pain: A road less traveled.

Authors:  Sukanya Mitra; Jasveer Singh; Kompal Jain; Swati Jindal
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2021-04-10

Review 6.  Chronic postoperative pain: ubiquitous and scarcely appraised: narrative review.

Authors:  Alexandre Lopes; Miriam Seligman Menezes; Guilherme Antonio Moreira de Barros
Journal:  Braz J Anesthesiol       Date:  2021-02-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.